October 2nd at 1 pm, don’t miss Bruno Almeida’s “IPLEXMED: Driving the Next Generation of Diagnostics from Lab to Life” at the A0.03 auditorium in UMinho’s School of Medicine.

IPLEXMED, a spin-off from the University of Minho and INL, is developing NEXAGUARD®—a portable, graphene-based diagnostic platform delivering lab-quality results in 20 minutes at the point of care or at home. Validated at TRL 6 with multiple patents filed, it targets bacterial respiratory infections and AMR, with plans to expand to STDs, sepsis, and hospital-acquired infections. Market launch is set for 2027 with a scalable “razor-and-blade” model, driving faster diagnostics, improved treatments, and lower healthcare costs worldwide.